FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia
MONTGOMERY, Ala. and MORRISVILLE, N.C., Aug. 3 /PRNewswire/ -- Kowa Research Institute (KRI) based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. ...
Genes Linked to Cholesterol in Cells Are Identified
...fore, some of the genes identified by us as regulators of cellular cholesterol in future studies might turn out to be disease genes that contribute to hypercholesterolemia
[high cholesterol] in some cases."
The genes identified in the study may also have potential as targets for new cholesterol-lowering drugs, the res...
Isis Reports Strong Financial Results and Highlights for First Quarter of 2009
...study evaluating mipomersen in homozygous Familial hypercholesterolemia
(FH) patients and from additional mipomersen studi...study evaluating mipomersen in homozygous Familial hypercholesterolemia
patients. We expect top-line data from this study...ed a Phase 3 study evaluating mipomersen in severe hypercholesterolemia
patients. This latest mipomersen study is the fou...
Sanofi-aventis Announces Good First-quarter 2009 Performance
... Phase III, saredutant is discontinued on the basis of results from the study in association with escitalopram in depression, AVE5530 is halted in hypercholesterolemia
due to insufficient efficacy, and the rights to TroVax (R) are returned to Oxford BioMedica. As regards vaccines, resources in the intercontinental z...
Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008
...study evaluating mipomersen in homozygous Familial hypercholesterolemia
(FH) patients and from additional mipomersen studi...e 3 studies in heterozygous FH subjects, high-risk hypercholesterolemia
and severe hypercholesterolemia
patients and a Phase 2 study in statin-intolerant ...
BioMed Realty Trust's Center for Life Science Boston Now 91% Leased
... business, Kowa is responsible for sales and marketing of innovative drugs and focuses on promoting cardiovascular drugs, such as a treatment drug for hypercholesterolemia
and hypertension through its owned subsidiary, Kowa Pharmaceutical Co. Ltd. In addition, Kowa has focused on lifestyle diseases (arteriosclerosis, kid...
Studies Challenge Framingham Risk Score
...ramingham Risk Score is validated up to age 75. There have been signs in the medical literature that the classic risk factors such as hypertension and hypercholesterolemia
[high cholesterol levels] were not performing that well for people with advanced age."
The new study "indicates that the traditional risk factors b...
AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights
... with progressive or asymmetric glaucoma despite normal eye pressure---especially in the presence of cardiovascular risk factors such as hypertension, hypercholesterolemia
or ischemia heart disease---for carotid artery Doppler scan to pick up those who could be at high risk for stroke and may benefit from carotid artery ...
Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
...t from Tulane University published on American Heart
Association's Journal of Circulation shows that due to lifestyle changes in
China, high levels of hypercholesterolemia
and low levels of awareness,
treatment, and information regarding same has made cardiovascular disease
the leading cause of death in China. As a leadi...
Lipid Association Responds to New Cholesterol Guidelines for Children
...that this is a health concern only
for middle-aged and elderly persons. In some affected children, such as
those with the inherited disorder, familial hypercholesterolemia
in those whose parent suffered coronary artery disease (CAD) before 50
years of age, atherosclerosis progresses more rapidly, leading to hear...
Hypercholesterolemia in Medical Technology
Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
First Presentation of Pivotal Study Data in Pediatric Patients
Presented at the American Heart Association's Annual Scientific Sessions
PARSIPPANY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo,
Inc. (DSI), announced today that results from the pivotal study supporting
the use ...
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012
in Familial Hypercholesterolemia Patients Presented at ACC
* Homozygous FH patients already being treated with maximally
tolerated lipid-lowering therapies experienced 50% further
reductions in LDL-C with similar reductions in other atherogenic
when treated with 300 mg/week ISIS 301012
NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS
301012 in Familial Hypercholesterolemia Patients
* Treatment with ISIS 301012 produced at least 45% additional
reduction in patients' LDL-cholesterol when added to
maximally-tolerated lipid-lowering therapies
CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. announced updated results from its ongoing
Phase 2 cli...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...full data from a Phase 3 study evaluating mipomersen in homozygous Familial hypercholesterolemia
(FH) patients; positive top line data was reported in May 2009
Report...filing in Europe shortly afterwards. Data from our Phase 3 study in severe hypercholesterolemia
patients should be available at the time of these U.S. submissions and may ...
Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
...sterol in a group of elderly patients with primary hypercholesterolemia
or combined dyslipidemia," said Professor Steen St...s aged more than or equal to 65 years with primary hypercholesterolemia
or combined dyslipidemia. About half of the patien... suitable statin for elderly patients with primary hypercholesterolemia
or combined dyslipidemia who are taking other medi...
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS )
today announced that they have begun a phase 3 study of mipomersen in
patients with heterozygous familial hypercholesterolemia
(heFH), a genetic
disorder that causes exceptionally high levels of LDL cholesterol. It is
the first of four new trials the companies plan to initiate...
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
... with interferon-alpha. TORISEL also
was associated with the development of hypercholesterolemia
of grade 2 or
higher, compared with interferon-alpha (P=0.001), but there w...us interferon-alpha (P=0.675).
However, the development of hyperglycemia or hypercholesterolemia
have affect on overall survival or progression-free survival in thi...
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
... 2 open-label extension (OLE) study of mipomersen in patients
with familial hypercholesterolemia
(FH). In FH patients exposed to
mipomersen for as long as 16 months, the sa...th high
cholesterol at high risk of cardiovascular events.
ABOUT FAMILIAL hypercholesterolemia
FH patients have high blood concentrations of LDL-cholesterol due to...
ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
...fects of the highest approved dose of VYTORIN/INEGY
versus the highest approved dose of simvastatin 80 mg alone in patients
with Heterozygous Familial hypercholesterolemia
(HeFH). The study was made
public by Merck/Schering-Plough Pharmaceuticals.
"The debate around the clinical study on cholesterol drugs has received
New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
...ined to prevent heart disease, heart attacks, or
strokes. For patients with hypercholesterolemia
and mixed dyslipidemia, the
usual recommended starting dose of CRESTOR is 1...nts, and patients with severe renal insufficiency. For patients
with marked hypercholesterolemia
(LDL-C >190 mg/dL) and aggressive lipid
targets, a 20-mg starting dose may ...
Hypercholesterolemia in Medical Definition
Lipoprotein/lipidemias: Hyperlipidemia - hypercholesterolemia
- Familial hypercholesterolemia
- Xanthoma - Combined hyperlipidemia - Lecithin cholesterol acyltrans...
Hypercholesterolemia in Medical Dictionary
is a genetic disorder characterized by high cholesterol levels, specifically very high low-density lipoprotein levels, in the blood and early cardiovascular disease. Many patients have mutations... Hypercholesterolemia
is the presence of high levels o...
is the presence of high levels of cholesterol in the blood. It is not a disease but a metabolic derangement that can be secondary to many diseas...
Hypercholesterolemia in Biological Technology
Isis Reports Financial Results and Highlights for Third Quarter of 2008
...atients and high-risk high cholesterol patients -- Report top line data on mipomersen from a Phase 2 liver imaging study in heterozygous Familial hypercholesterolemia
(FH) patients -- Provide an update on mipomersen from an ongoing open-label extension study in patients with FH -- Report Phase 2 study data in ...
Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
...gy to lower Total-C and LDL-C to target levels. CRESTOR has not been
determined to prevent heart disease, heart attacks, or strokes. For
patients with hypercholesterolemia
and mixed dyslipidemia, the usual
recommended starting dose of CRESTOR is 10 mg. The 40-mg dose of CRESTOR is
reserved only for those patients who hav...
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Upcoming Key Milestones -- Initiate three trials in addition to the Phase 3 study in patients with heterozygous Familial hypercholesterolemia
(FH) announced this week, studying mipomersen in apheresis-eligible patients and high-risk high cholesterol patients -- Present liver imag...
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
...lone has been inadequate, to reduce elevated total cholesterol,
LDL- C, Apo B, and triglyceride levels, and to increase HDL-C in patients
with primary hypercholesterolemia
and mixed dyslipidemia. In patients with
a history of myocardial infarction and hypercholesterolemia, niacin is
indicated to reduce the risk of recurr...
Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
...s in the prevention
of coronary disease, the nation's top killer.
"Atherotech believes that precise physician decisions about lifelong
management of hypercholesterolemia
can only be accomplished with a detailed
profiling of lipoprotein components," said Atherotech Chief Medical Officer
James Ehrlich, M.D. "By identifyi...
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
...ce under the
Hart-Scott-Rodino Antitrust Improvements Act.
About Familial hypercholesterolemia
FH patients have high blood concentrations of LDL-cholesterol due to... of premature cardiovascular
diseases (CVD) and CVD-related death. Familial hypercholesterolemia
present in two forms: homozygous (hoFH), where the same defective ge...
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
... in the treatment of diseases, the etiology of
which is misrouted or misfolded proteins, for example, cystic fibrosis,
nephrogenic diabetes insipidus, hypercholesterolemia
and others. Axentis is
managed by a team of experienced entrepreneurs.
About aRigen Pharmaceuticals, Inc. ( http://www.arigen.jp )
Genzyme Launches Cholestagel(R) in Europe
... New Therapy Helps Lower Cholesterol in Primary hypercholesterolemia
CAMBRIDG...gel as an add-on therapy
in patients with familial hypercholesterolemia
(FH) -- an inherited
disorder that causes exceptio...s with
peripheral arterial disease. About Primary hypercholesterolemia
New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
...cated alone or in combination with a
statin, as an adjunct to diet and exercise for the reduction of elevated
LDL cholesterol in patients with primary hypercholesterolemia
Type IIa) when the response to diet and exercise has been inadequate.
Liver- function monitoring is not required with WelChol when used a...